Deltacel is under clinical development by Kiromic BioPharma and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Deltacel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deltacel overview

Deltacel is under development for the treatment of non-small cell lung cancer and metastatic squamous cell carcinoma. It is administered through parenteral and intravenous route. It comprises of allogenic, non-viral, non-engineered gamma delta T-cells and is being developed based on ABBIE, non-viral genome editing technology and DIAMOND artificial intelligence and data mining platform. The therapeutic candidate was also under development for relapsed B cell acute lymphoblastic leukemia, non-small cell lung cancer and large B cell lymphoma.

Kiromic BioPharma overview

Kiromic BioPharma (Kiromic) discovers and develops immuno-oncology therapies using gene-editing technologies. The company is investigating ALEXIS PRO-1, an allogeneic GDT therapy product targeting PD-L1 for the treatment of solid tumor; and ALEXIS ISO-1, targeting an isoform of Mesothelin present on tumor cells. It utilizes Diamond, an artificial intelligence bioinformatics approach to identify new cancer immunological targets for T cells; and ABBIE, a non-viral genome editing mechanism to insert target DNA template information into the genome of a host cell. The company works in collaboration with biotechnology and pharmaceutical companies to develop its products. Kiromic is headquartered in Houston, Texas, the US.

For a complete picture of Deltacel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.